85774-09-0

Usage

Uses

Used in Pharmaceutical Industry:
METHYL D-HOMOALANINATE HCL is used as a reagent for the synthesis of pteridine derivatives, which possess antibacterial and antifungal activities. These derivatives are valuable in the development of new drugs to combat resistant infections and improve treatment options for various diseases.
METHYL D-HOMOALANINATE HCL is also used as a reagent in the synthesis of diazepanones, which act as dipeptidyl peptidase IV inhibitors. These inhibitors play a crucial role in the regulation of glucose levels in the body, making them potential candidates for the treatment of type 2 diabetes and other related metabolic disorders.

InChI:InChI=1/C5H11NO2.ClH/c1-3-4(6)5(7)8-2;/h4H,3,6H2,1-2H3;1H/t4-;/m1./s1

Upstream product

• 67-56-1 methanol 
• 1492-24-6 L-2-aminobutyric acid 
• 861889-32-9 methyl 2-[(diphenylphosphoryl)amino]butanoate 
• 2623-91-8 (R)-2-aminobutyric acid 
• 34306-42-8 Boc-Abu 
• 5959-29-5 S-(+)-2-amino-n-butyric acid hydrochloride 
• 75266-41-0 (S)-2-amino-but-3-enoic acid methyl ester hydrochloride 

Downstream Products

• 22839-32-3 Benzyloxycarbonyl-L-β-amino-β-phenyl-propionyl-L-α-amino-buttersaeuremethylester 
• 767570-56-9 L-Abu-NHMe 
• 7324-11-0 (S)-2-amino-butanamide 
• 208256-00-2 N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester 
• 208256-04-6 N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester 
• 53726-14-0 (S)-2-amino-butanamide hydrochloride 
• 1331960-93-0 (R)-5-((S)-1-methoxy-1-oxobutan-2-ylamino)-5-oxo-4-(3,4,5-trimethoxybenzamido)pentanoic acid 
• 151445-12-4 (R)-2-(2-Nitro-phenylsulfanylamino)-butyric acid methyl ester 
• 767570-56-9 D-Abu-NMe 
• 3828-69-1 N-(N-Benzyoxycarbonyl-L-threonyl)-D-2-amino-buttersaeure-methylester 
• 755039-52-2 (R)-methyl 2-(cyclopentylamino)butanoate 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4

The simultaneous inhibition of PLK1 and BRD4 by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Herein, two series of novel pteridinone derivatives possessing a sulfonyl moiety were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against HCT116, PC3 and BT474 cell lines. Among them, the most promising compound B2 showed high antiproliferative effects on the three cell lines with IC50 values of 0.30 μM, 1.82 μM and 1.69 μM, respectively. In the enzymatic assay, B2 was identified as a potent PLK1 and BRD4 dual inhibitor (PLK1 IC50 = 6.3 nM, BRD4 IC50 = 179 nM). Further explorations in bioactivity were conducted to clarify the anticancer mechanism of compound B2. The results showed that compound B2 obviously inhibited the proliferation of HCT116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of HCT116 cells and arrested the G2 phase of HCT116 cells.

Expanding the Protecting Group Scope for the Carbonyl Olefin Metathesis Approach to 2,5-Dihydropyrroles

Chiral pyrrolidine derivatives are important building blocks for natural product synthesis. Carbonyl olefin metathesis has recently emerged as a powerful tool for the construction of such building blocks from chiral amino acid derivatives. Here, we demons

Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors

Protein kinase inhibitors and epigenetic regulatory molecules are two main kinds of anticancer drugs developed in recent years. Both kinds of drugs harbor their own advantages and disadvantages in the treatment of cancer, and the development of small mole

Pyrimidinyl-piperazine-1, 2, 4-triazole derivative, and preparation method and application thereof

The invention discloses a pyrimidinyl-piperazine-1, 2, 4-triazole derivative, and a preparation method and application thereof. The structural formula of the compound is shown in the specification. Inthe formula, R1 is a chain or cyclic aliphatic hydrocar

Preparation method of (S)-(+)-2-aminobutanamide hydrochloride

The invention discloses a preparation method of (S)-(+)-2-aminobutanamide hydrochloride, and relates to a preparation method of a levetiracetam key intermediate, and the method comprises the followingspecific steps: carrying out esterification reaction on L-2-aminobutyric acid serving as a starting material and thionyl chloride, and concentrating part of solvent after the reaction is finished; introducing ammonia gas to neutralize generated hydrogen chloride and residual thionyl chloride; and filtering, introducing ammonia gas, and carrying out an ammonolysis reaction to obtain the (S)-2-aminobutanamide hydrochloride after the treating is finished. According to the preparation method, the starting material is simple and easy to obtain, the one-pot method is adopted, the atom utilization rate is high, operation is easy and convenient, and the obtained product quality is high.

Method for preparing levetiracetam

The invention relates to a method for preparing levetiracetam. The method comprises the following steps: reacting aminobutyric acid in lower alcohol and thionyl chloride to obtain an intermediate I; adding ammonia water to continue the reaction, and adding hydrochloric acid to adjust the pH value to about 3 to salify to obtain a salified intermediate II refined product; reacting the intermediate II in the presence of KOH in the presence of a catalyst and dichloromethane, and then adding 4-chlorobutyryl chloride to continuously react; adding water to hydrolyze, adjusting the pH to be weakly alkaline by using diluted hydrochloric acid, and crystallizing to obtain a levetiracetam crude product; decolorizing and crystallizing in ethyl acetate to obtain a refined product of levetiracetam. The invention also relates to the levetiracetam prepared by the method and pharmaceutical application thereof, for example, the levetiracetam can be used for treating or preventing epilepsy, Parkinson's disease, dyskinesia, migraine, tremor, idiopathic tremor, bipolar disorder, chronic pain, neuropathic pain, or bronchial, asthma or allergic diseases.

Compound or salt or solvate thereof, application thereof and pharmaceutical composition

The invention relates to the field of pharmacy, in particular to a compound or salt or solvate thereof, application thereof and a pharmaceutical composition. The invention provides a compound shown asformula (I) or a salt or solvate thereof, wherein X is

Cyano-substituted cyclic hydrazine derivatives and application thereof

The invention provides cyano-substituted cyclic hydrazine derivatives. The cyano-substituted cyclic hydrazine derivatives are characterized in that the cyano-substituted cyclic hydrazine derivatives are compounds as shown in the following structural formula shown in the specification or stereoisomers, geometrical isomers, tautomers, racemates, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof; the compounds are useful for the prevention, treatment, treatment or amelioration of autoimmune diseases or proliferative diseases in patients, and/or for the inhibition or modulation of protein kinase activity.

Rhodium-Catalyzed Enantioselective Synthesis of Oxazinones via an Asymmetric Ring Opening-Lactonization Cascade of Oxabicyclic Alkenes

The rhodium-catalyzed asymmetric ring opening reaction of oxabicyclic alkenes is shown to be an efficient method for synthesizing chiral heterocycles. We demonstrate that the pairwise combination of chiral catalyst with chiral amino-acid-derived pronucleophiles results in a stereodivergent synthesis of diastereomeric hydroxyesters. A favorable conformational preference induces the subsequent lactonization of one diastereomer leading to the highly enantioselective synthesis of oxazinones.

Method for preparing levetiracetam

The invention relates to the technical field of drug synthesis, and provides a method for preparing levetiracetam. The method includes the following steps: taking L-2-aminobutyric acid as a starting material, and preforming esterification with thionyl chloride to obtain (S)-2-methyl aminobutyrate hydrochloride; performing aminolysis reaction between the (S)-2-methyl aminobutyrate hydrochloride andammonia water to generate (S)-2-aminobutylamine hydrochloride; preforming acylation reaction between the(S)-2-aminobutylamine hydrochloride and the mixed solution of 4-chlorobutyryl chloride and dichloromethane; directly performing cyclization reaction between the intermediate product with the dichloromethane and tetrabutyl ammonium bromide to obtain a crude product of levetiracetam; and recrystallizing the crude product to generate the levetiracetam. The preparation method uses the easily-obtained starting material to ensure good reproducibility of the synthesis route, simple unit operationand economic accounting. The reaction in each step is easy to purify, the quality is controllable, and the reaction yield is greatly improved.